| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 28, 2003
From Internal Medicine-Dermatology Department (N.A., S.B., J.-C.P., C.F.), Pitié-Salpêtrière Hospital, Paris; and Haematology Department (G.E., C.S.), Lariboisière Hospital, Paris, France. * To whom correspondence should be addressed. E-mail: camille.frances{at}psl.ap-hop-paris.fr.
Background--Sneddons syndrome is characterized by the association of ischemic cerebrovascular events and widespread livedo racemosa. The pathophysiology of Sneddons syndrome remains elusive, but various prothrombotic abnormalities have been previously reported in this setting. Low levels of protein Z, a downregulator of coagulation, have been recently linked to an increased risk of arterial thrombosis. The purpose of this study was to investigate the levels of protein Z in a series of Sneddons syndrome patients without circulating antiphospholipid antibodies in comparison with an age- and sex-matched control population. Methods--Twenty-six patients and 78 healthy controls had determination of their protein Z blood levels by an enzyme-linked immunoassay test. Patients thrombotic and vascular risk factors, including tobacco smoking, arterial hypertension, oral contraceptive agents, dyslipidemia, factor V Leiden, and factor II mutation were recorded. Results--Protein Z plasma levels were significantly lower in patients (mean 1.47 mg/L) than in controls (mean 1.93 mg/L) (P=0.02). Prevalence of protein Z deficiency (level <1 mg/L) was significantly higher (P=0.001) among patients (31%) than among controls (3.8%). Factor V Leiden and heavy smoking were observed in 4 and 7 patients, respectively. Conclusions--Sneddons syndrome could be viewed as the peculiar clinical expression of various and sometimes associated coagulation abnormalities. Low levels of protein Z may account, at least partly, for the thrombotic events observed in Sneddons syndrome and shed a new light on its pathophysiology. Clinical implications for protein Z deficiency in this setting deserve further investigations.
Revised on January 7, 2004
Accepted on February 10, 2004
Protein Z Deficiency in Antiphospholipid-Negative Sneddons Syndrome
Nakhlé Ayoub MD;
This article has been cited by other articles:
![]() |
M. J. Heeb, K. M. Cabral, and L. Ruan Down-regulation of Factor IXa in the Factor Xase Complex by Protein Z-dependent Protease Inhibitor J. Biol. Chem., October 7, 2005; 280(40): 33819 - 33825. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Staton, M. Sayer, G.J. Hankey, V. Cole, J. Thom, and J.W. Eikelboom Protein Z Gene Polymorphisms, Protein Z Concentrations, and Ischemic Stroke Stroke, June 1, 2005; 36(6): 1123 - 1127. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |